Pestivirus control programs: how far have we come and where are we going?

被引:67
|
作者
Moennig, Volker [1 ]
Becher, Paul [1 ]
机构
[1] Univ Vet Med, Inst Virol, Dept Infect Dis, D-30559 Hannover, Germany
关键词
bovine viral diarrhea; classical swine fever; pestivirus control; BOVINE VIRAL DIARRHEA; CLASSICAL SWINE-FEVER; VIRUS BVDV INFECTIONS; ORAL IMMUNIZATION; FETAL PROTECTION; VACCINATION; CATTLE; VACCINES; DISEASE; ERADICATION;
D O I
10.1017/S1466252315000092
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Classical swine fever (CSF) is endemic in large parts of the world and it is a major threat to the pig industry in general. Vaccination and stamping out have been the most successful tools for the control and elimination of the disease. The systematic use of modified live vaccines (MLV), which are very efficacious and safe, has often preceded the elimination of CSF from regions or countries. Oral vaccination using MLV is a powerful tool for the elimination of CSF from wild boar populations. Bovine virus diarrhea (BVD) is endemic in bovine populations worldwide and programs for its control are only slowly gaining ground. With two genotypes BVD virus (BVDV) is genetically more diverse than CSF virus (CSFV). BVDV crosses the placenta of pregnant cattle resulting in the birth of persistently infected (PI) calves. PI animals shed enormous amounts of virus for the rest of their lives and they are the reservoir for the spread of BVDV in cattle populations. They are the main reason for the failure of conventional control strategies based on vaccination only. In Europe two different approaches for the successful control of BVD are being used: Elimination of PI animals without or with the optional use of vaccines, respectively.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
  • [1] HOW FAR HAVE WE COME - WHERE ARE WE GOING
    HOOPER, JF
    JOURNAL OF RANGE MANAGEMENT, 1968, 21 (03): : 186 - &
  • [2] Vaccination of travelers: how far have we come and where are we going?
    Chen, Lin H.
    Hill, David R.
    Wilder-Smith, Annelies
    EXPERT REVIEW OF VACCINES, 2011, 10 (11) : 1609 - 1620
  • [3] Tobacco control approaches and inequity-how far have we come and where are we going?
    Purcell, Kate R.
    O'Rourke, Kerryn
    Rivis, Maya
    HEALTH PROMOTION INTERNATIONAL, 2015, 30 : 89 - 101
  • [4] VIRAL-HEPATITIS - HOW FAR WE HAVE COME, WHERE WE ARE GOING
    DIENSTAG, JL
    DRUG THERAPY, 1978, 8 (09) : 31 - 33
  • [5] Picosecond diffraction at the ESRF: How far have we come and where are we going?
    Wulff, Michael
    Kong, Qingyu
    Cammarata, Marco
    Lo Russo, Manuela
    Anfinrud, Philip
    Schotte, Friedrich
    Lorenc, Maciej
    Ihee, Hyotcherl
    Kim, Tae Kyu
    Plech, Anton
    SYNCHROTRON RADIATION INSTRUMENTATION, PTS 1 AND 2, 2007, 879 : 1187 - +
  • [6] A reflection on mathematical cognition: how far have we come and where are we going?
    Umland, Kristin
    MATHEMATICS ENTHUSIAST, 2008, 5 (01): : 101 - 116
  • [7] Pharmacogenetics in clinical practice: how far have we come and where are we going?
    Johnson, Julie A.
    PHARMACOGENOMICS, 2013, 14 (07) : 835 - 843
  • [8] The status of agroforestry in the United States: How far have we come, where are we going?
    Rietveld, WJ
    MEETING IN THE MIDDLE, PROCEEDINGS, 1997, : 151 - 156
  • [10] Commentary on: Pancreatic cancer since halsted: How far have we come and where are we going?
    Mahvi, DM
    Breslin, TM
    ANNALS OF SURGERY, 2003, 238 (06) : S145 - S147